Top ten highlights from the APAC PE, VC, and startup ecosystem this week:
- Indian Startups See Decrease in Funding: Indian startups experienced a 17% drop in funding in December, totaling $1.38 billion compared to $1.66 billion in November.
- Robust Activity in Indian Healthcare Sector: The healthcare sector in India saw significant deal activity in 2024, with $5.67 billion invested in various healthcare firms.
- India Stands Out in Asia-Pacific PE Deals: India accounted for 26% of the total private equity deal volume in the healthcare sector in the Asia-Pacific region.
- Positive Outlook for Indian Healthcare Sector: Industry experts predict a continued growth trajectory for the Indian healthcare sector in the coming year.
- Strong Performance in India’s IPO Market: The IPO market in India had a successful run in 2024 and is projected to maintain its momentum in 2025 with record-breaking volumes.
- LP-GP News: Impact-focused private capital investors are gearing up for secondaries transactions, opening up new opportunities in the impact investment space.
- Bain Capital Explores Investments in Indonesia: Bain Capital is looking into investment opportunities beyond healthcare in Indonesia.
- Chinese Semiconductor Fund Backs New Ventures: China’s state-backed investment fund for chipmaking has started backing new funds amid increasing pressures from the US.
- BlackRock’s Exit from Net Zero Asset Managers Initiative: BlackRock, the world’s largest asset manager, announced its departure from an environmentally-focused investor group.
- Funding Updates in Southeast Asia and Beyond: Various companies in Indonesia, Singapore, Vietnam, and other regions announce new rounds of funding and strategic initiatives.
APAC Private Markets Research
Explore latest Insights on APAC Private Markets on Smartkarma
Disclaimer:This article by is general in nature and based on publicly available information and not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material. While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
Also, check out the latest in ECM Research on Smartkarma
